

 Open access • Posted Content • DOI:10.1101/2020.01.31.925156

Quantifying protein-protein interactions by molecular counting with mass photometry — [Source link](#)

[Fabian Soltermann](#), [Eric D. B. Foley](#), [Veronica Pagnoni](#), [Martin R. Galpin](#) ...+3 more authors

Institutions: [University of Oxford](#)

Published on: 31 Jan 2020 - [bioRxiv](#) (Cold Spring Harbor Laboratory)

Related papers:

- [Quantifying protein-protein interactions by molecular counting with mass photometry](#)
- [Single molecule mass photometry of nucleic acids](#)
- [Mass photometry enables label-free tracking and mass measurement of single proteins on lipid bilayers.](#)
- [Quantitative mass imaging of single biological macromolecules](#)
- [Learning to count: determining the stoichiometry of bio-molecular complexes using fluorescence microscopy and statistical modelling](#)

Share this paper:    

View more about this paper here: <https://typeset.io/papers/quantifying-protein-protein-interactions-by-molecular-4eicflj47u>

Single-Molecule Studies **Hot Paper**How to cite: *Angew. Chem. Int. Ed.* **2020**, 59, 10774–10779

International Edition: doi.org/10.1002/anie.202001578

German Edition: doi.org/10.1002/ange.202001578



Quantifying Protein–Protein Interactions by Molecular Counting with Mass Photometry

Fabian Soltermann, Eric D. B. Foley, Veronica Pagnoni, Martin Galpin,
Justin L. P. Benesch, Philipp Kukura,* and Weston B. Struwe*



Abstract: Interactions between biomolecules control the processes of life in health and their malfunction in disease, making their characterization and quantification essential. Immobilization- and label-free analytical techniques are desirable because of their simplicity and minimal invasiveness, but they struggle with quantifying tight interactions. Here, we show that mass photometry can accurately count, distinguish by molecular mass, and thereby reveal the relative abundances of different unlabelled biomolecules and their complexes in mixtures at the single-molecule level. These measurements determine binding affinities over four orders of magnitude at equilibrium for both simple and complex stoichiometries within minutes, as well as the associated kinetics. These results introduce mass photometry as a rapid, simple and label-free method for studying sub-micromolar binding affinities, with potential for extension towards a universal approach for characterizing complex biomolecular interactions.

Understanding how biomolecules interact with each other is central to the life sciences. The complexity thereof ranges from specific binary interactions, such as between antibodies and antigens,^[1–3] to the formation of complex macromolecular machines.^[4,5] Conversely, undesired interactions are often associated with disease, such as the formation of protein aggregates in neurodegenerative disease,^[6] or the engagement of a virus with its target cell.^[7,8] The high specificity and critical role of these interactions make them an ideal target for intervention, either in promoting a certain response by presenting an alternative binding partner, or preventing (dis)assembly.^[9–11] This diversity comes with a broad range of binding strengths and dynamics, measured in terms of thermodynamic and kinetic quantities such as equilibrium constants (e.g. for dissociation, K_d), free energies, and rate constants (k_{off} and k_{on}).

In broad terms, existing biophysical methods can be categorized into size-based approaches performing quantification and separation by either size or diffusion coefficient, physical interaction with functionalized surfaces, direct mass measurement, enthalpy changes, or light scattering.^[12–17] These ensemble-based methods are complemented by fluorescence-based approaches^[18] capable of operating at the single-molecule level, providing additional information on sample heterogeneity and dynamics.^[19,20] All of the above methods operate in the context of various practical short-

comings such as non-native environments, artefacts caused by protein immobilization and labelling, lack of sensitivity at low concentrations, or lack of resolution.^[21–23] Biological systems can pose additional challenges from either particularly fast or slow kinetics to complexities arising from multiple co-existing species. Label-free methods struggle with strong binding affinities ($K_d < \mu\text{M}$), which are often encountered for interactions of relevance for biopharmaceuticals in the context of antibody-based drugs.^[24]

We have recently developed mass photometry (MP), originally introduced as interferometric scattering mass spectrometry (iSCAMS), as a means for detecting and measuring the mass of single proteins and the complexes they form in solution.^[26] MP detects single biomolecules by their light scattering as they bind nonspecifically to a microscope cover glass surface. Each binding event leads to a change in refractive index at the glass/water interface, which effectively alters the local reflectivity and can be detected with high accuracy by taking advantage of optimized interference between scattered and reflected light (Figure 1a).^[25] The reflectivity change is proportional to the molecular mass, with up to 20 kDa mass resolution and 2% mass accuracy by calibration with biomolecules of known mass.^[26] Both the original^[26] and subsequent studies have proposed methods to extract binding affinities from MP distributions of biomolecular mixtures,^[27] and shown that the results agree broadly with alternative approaches.^[26–28] The degree to which these MP distributions are indeed quantita-




Figure 1. Principle of single-molecule counting by mass photometry. a) Label-free single-molecule detection by imaging the interference of scattered and reflected light arising from individual protein landing events at a glass-water interface over time. b) Scatter plot of single-molecule contrasts and resulting mass distribution for a 1:1 monomer/dimer 2G12 mixture. c) Mass distributions for varying 2G12 monomer/dimer ratios. d) Comparison of monomer/dimer ratios measured by MP compared to expectations based on UV-VIS absorption characterization.

[*] F. Soltermann, E. D. B. Foley, V. Pagnoni, Dr. M. Galpin, Prof. J. L. P. Benesch, Prof. P. Kukura, Dr. W. B. Struwe
Physical and Theoretical Chemistry, Department of Chemistry,
University of Oxford
South Parks Road, Oxford, OX1 3TA (UK)
E-mail: philipp.kukura@chem.ox.ac.uk
weston.struwe@chem.ox.ac.uk

Supporting information and the ORCID identification number(s) for the author(s) of this article can be found under:
<https://doi.org/10.1002/anie.202001578>.

© 2020 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

tive, and how they can be used to efficiently extract not only binding affinities but also kinetics, however, remain unexplored.

Label-free single-molecule detection in principle provides the purest and most direct measurement of sample concentration by counting individual molecules. To explore this capability in the context of biomolecules, we chose monomers and domain exchanged dimers of the HIV-1 neutralizing antibody 2G12 (see Figures S1–S3 in the Supporting Information), which produced mass distributions with the expected major bands at 147 kDa and 291 kDa (Figure 1b). Repeating these experiments for monomer/dimer ratios ranging from 0.15 to 8.1 (Figure 1c) revealed close agreement with UV-VIS-based characterization within the experimental error (4.6% RMS), except for noticeable deviations ($\approx 20\%$) for

the lowest ratios (Figure 1d). We found that such deviations could almost exclusively be attributed to sample preparation, such as an additional dilution step required to reach subnanomolar concentrations, leading to variations in counts arising from nonspecific protein adsorption to the sample tube (see Figures S4 and S5).

Equipped with these benchmarking results, we set out to investigate the suitability of MP to characterize interactions of varying affinities, using the immunoglobulin G (IgG) monoclonal antibody trastuzumab (Herceptin[®]) binding to soluble domains of IgG Fc receptors or ErbB2 (HER2) antigens. Trastuzumab, herein referred to as IgG, and Fc γ R1a by themselves revealed monodisperse distributions at 154 ± 1 kDa and 50 ± 1 kDa, respectively (Figure 2a, see Figure S6). A 1:1 Fc γ R1a-IgG mixture resulted in a large IgG-




Figure 2. Single-shot K_d and kinetics measurements of IgG-Fc γ R1a interactions. a) MP mass distributions of IgG (red), Fc γ R1a (purple) and a 1:1 mixture of IgG-Fc γ R1a (blue). b) MP distributions of deglycosylated IgG (red), Fc γ R1a (black) and 1:1 mixture of IgG-Fc γ R1a (blue). c) Mass distributions for a 1:1 mixture of deglycosylated IgG-Fc γ R1a at total IgG concentrations ranging from 300 pM to 5 nM and respective K_d calculated from a single-shot measurement. d) Mass distributions for a 1:1 mixture of deglycosylated IgG-Fc γ R1a at 1.5 nM total IgG concentration, ranging from 0 to 30 minutes after dilution from 2.9 μ M. e, f) Mole fraction of assembled IgG-Fc γ R1a and deglycosylated IgG-Fc γ R1a complexes as a function of time after dilution from 2.7 μ M to 0.3 nM total IgG concentration, and 2.6 μ M to 5 nM total deglycosylated IgG concentration and corresponding single exponential fits. g, h) Corresponding SPR analysis of IgG-Fc γ R1a and deglycosylated IgG-Fc γ R1a (h).

Fc γ RIa complex peak, corresponding to about a 90% complex formation, from which we can extract an apparent $K_d = 50 \pm 10$ pM by counting bound and unbound species in combination with knowledge of the total protein concentration [see Equations (S1)–(S6) and Figure S7]. IgG N-glycan removal (see Figure S8) weakened FcR binding^[29] resulting in a 1:1 mixture of Fc γ RIa and deglycosylated IgG exhibiting considerably less bound antibody (ca. 50%; Figure 2b), corresponding to an apparent $K_d = 1.0 \pm 0.1$ nM (see Figure S9).

This simple single-shot approach presented so far produces results in a few minutes, however, necessarily neglects the importance of kinetics and equilibration conditions. To address this, we probed Fc γ RIa binding to deglycosylated IgG at a 1:1 ratio. Samples were mixed at 4 μ M concentrations, incubated for 15 minutes, and diluted to 5, 1, and 0.3 nM as final protein concentrations (Figure 2c; see Figure S10). At concentrations above the K_d value we found mostly bound complexes, with free species dominating below the K_d value, but all measurements yielded similar binding affinities ($K_d = 1.0 \pm 0.1$, 0.6 ± 0.1 and 0.7 ± 0.3 nM), suggesting that they were performed at or close to equilibrium (see Figure S11). These binding affinities were confirmed after equilibration time screening (see Figures S12 and S13).

For quantification of the tighter interaction between Fc γ RIa and IgG, screening at a range of concentrations was essential to ensure that the observed mass distributions were representative of the interaction to be quantified (see Figures S14–S16). As an additional example, for the HER2–IgG interaction, a simple single-shot experiment at nanomolar concentration would have led to $K_{d,1} = 1.4 \pm 0.1$ nM and $K_{d,2} = 4.8 \pm 0.3$ nM (see Figure S17). Recording distributions at a few different concentrations, however, revealed a linear dependence of our K_d values on sample concentration, indicating a very tight $K_d < 70$ pM, and/or slow interactions with off-rates on the order of hours. Therefore, performing a few measurements at a range of concentrations is crucial to prevent misinterpreting data derived from a single-shot K_d approach for very strong interactions. Irrespective, our method provides rapid and clear distinction between interactions with vastly different binding affinities, which only need to be refined if highly accurate measurements are required.

The importance of (dis)association rates in addition to thermodynamic quantities raises the question to which degree we can use MP to directly visualize and quantify interaction kinetics. As MP measurements currently take place in the < 100 nM concentration range, we should be able to access dissociation kinetics by simply diluting to total protein concentrations around the estimated K_d (approx. 1:1 ratio bound: unbound species for a 1:1 interaction), and monitoring the bound/unbound ratio throughout (Figure 2f, see Figure S18a). The observed exponential decay reveals the desired kinetic information, while the plateau yields the K_d value, ultimately enabling us to determine k_{off} and k_{on} . For Fc γ RIa binding to deglycosylated IgG, this approach yielded $K_d = 1.1 \pm 0.2$ nM in good agreement with our single-shot measurements (Figure 2c), with $k_{on} = 6.0 \pm 1.7 \times 10^6$ M⁻¹ s⁻¹ and $k_{off} = 6.8 \pm 1.6 \times 10^{-3}$ s⁻¹. The corresponding experiment

with glycosylated IgG–Fc γ RIa yielded $K_d = 26 \pm 22$ pM with an off-rate one order of magnitude slower ($5.2 \pm 2.5 \times 10^{-4}$ s⁻¹) than for deglycosylated IgG but an almost identical on-rate ($1.9 \pm 1.1 \times 10^7$ M⁻¹ s⁻¹; Figure 2e), again in good agreement with our single-shot screening data (see Figures S15 and S16). The difference in K_d values between the glycosylated and deglycosylated IgG originates mostly from the off-rate caused by protein–protein interactions (see Figure S19), confirming that the glycans are critical for tight binding. Association measurements (see Figures S18b, S20, and S21) can in principle be used in an analogous fashion, although we found it more susceptible to protein loss because of nonspecific adsorption (see Figures S22–S24). Overall, our results were in good agreement with SPR measurements (Figures 2e,f), subject to on-rate variations expected from a matrix and surface-immobilization-based approach compared to ours, where all interactions take place in free solution (see Figure S25).

A key advantage of MP over existing solution-based approaches is our ability to distinguish directly between different species contributing to a multicomponent system, as given by the IgG:FcRn interaction involving as many as five different interacting species. FcRn regulates serum IgG half-life and transcytosis to the fetus by a pH gradient in endosomes, yet the interplay between self-assembly and IgG binding is disputed,^[30,31] which are both important factors in biotherapeutic design. Based on the existing literature we based our calculations on the independent free monomer binding model (see Figure S26a). At pH 5 FcRn formed monomers and dimers with a $K_d = 31 \pm 11$ nM (Figure 3a; see Figure S27). At pH 5.5 and pH 6, only negligible amounts of FcRn dimers were present with a FcRn monomer-dimer $K_d > 200$ nM (see Figures S28 and S29). The resulting K_d values for the IgG–FcRn interaction, at pH 5, were 44 ± 9 nM for the monomer-dimer equilibrium, 59 ± 8 nM for the IgG–FcRn_{monomer}, and 6.6 ± 0.6 nM for IgG plus two FcRns [see Figure S30 and Equations (S7)–(S18)]. Increasing the pH value to 5.5 decreased the binding affinities to 171 ± 19 nM and 225 ± 20 nM but did not significantly affect the binding affinity of IgG plus two FcRns of 3.9 ± 1.5 nM (Figure 3b; see Figures S31 and S32), contrasting SPR results for similar systems reporting an ensemble $K_d = 760 \pm 60$ nM for all interactions.^[31] At pH 6 and 7, our current sensitivity only allowed an estimate of the binding affinities to be $K_d > 200$ nM (Figure 3b; see Figures S33 and S34). These results highlight pH-dependent FcRn dynamics and IgG engagement, and reveal cooperativity where the second receptor binds IgG tighter than the first and with a weaker pH sensitivity.

Taken together, we have demonstrated that molecular counting with MP is sensitive, quantitative, and accurate in determining the relative abundances of different biomolecules and their complexes in solution. When implemented in the vicinity of the binding affinity, a single measurement lasting typically 30 seconds, or 240 seconds for continuous flow injection, yields accurate binding affinities spanning four orders of magnitude from 30 pM to 200 nM, while enabling kinetic probing with a time-resolution on the order of 30 seconds in the range of minutes to hours. As a result, MP




Figure 3. Binding stoichiometry and affinity of the IgG-FcRn interaction as a function of pH. a) Self-assembly of FcRn dimers at pH 5 (red) and 5.5 (dotted red) and equivalent pH measurements of IgG at pH 5 (grey) and 5.5 (dotted grey). b) IgG-FcRn complexes (1:1 mixture) at pH 5, 5.5 and 6. c) Associated pH dependent binding affinities of interaction revealing cooperativity in FcRn binding (PDB: 4N0U, 3FRU).

affords real-time assessment of (dis)assembly completely label-free and independent of protein immobilization to a surface, thus minimizing any possible perturbations, as well as being intrinsically sensitive to binding stoichiometries and oligomerization. The current limitation to sub-micromolar affinities and concentration range can be addressed in the future through combination with fluidic approaches,^[32] as well as improvements to hardware and software, with which we expect to reach the micromolar range in the future. This range will enable measurements up to 100 μ M affinities, making MP a powerful approach for characterizing biomolecular interactions without labels and single-molecule sensitivity in a minimally perturbative fashion. Furthermore, the applicability of MP to both nucleic acids^[33] and large multimolecular machines^[34] provides scope for MP becoming a universal tool for studying biomolecular interactions and dynamics in a rapid, label-free, yet single-molecule-sensitive fashion.

Experimental Section

Protein preparation, mass photometry, data analysis as well as supplementary figures and equations are described in the Supporting Information.

Acknowledgements

We thank Mohammed Khan and Ben Davis, University of Oxford, for supplying deglycosylated trastuzumab and discussions, Stephan Burkhalter, ETH Zurich and PSI, for contributions to the analysis code, Andrew Baldwin, University of Oxford for helpful discussion, David Staunton, University of Oxford for assisting in SPR measurements, and Daniel Cole for the construction of the mass photometer. This work was supported by funding from the Engineering and Physical Sciences Research Council (EPSRC) and Medical Research Council (MRC) [grant number EP/L016052/1]. W.B.S. was supported by Refeyn Ltd. The authors recognize support from an ERC Consolidator Grant (PHO-TOMASS 819593).

Conflict of interest

P.K. is an academic founder, shareholder and director to Refeyn Ltd. J.L.P.B. is an academic founder, shareholder and consultant to Refeyn Ltd. W.B.S. is a shareholder and consultant to Refeyn Ltd. All other authors declare no conflict of interest.

Keywords: antibodies · mass photometry · protein–protein interactions · receptors · single-molecule studies

- [1] D. A. Calarese, C. N. Scanlan, M. B. Zwick, S. Deechongkit, Y. Mimura, R. Kunert, P. Zhu, M. R. Wormald, R. L. Stanfield, K. H. Roux, et al., *Science* **2003**, *300*, 2065–2071.
- [2] H. T. Lee, S. H. Lee, Y. S. Heo, *Molecules* **2019**, *4*, 1–16.
- [3] H. P. Peng, K. H. Lee, J. W. Jian, A. S. Yang, *Proc. Natl. Acad. Sci. USA* **2014**, *111*, E2656–E2665.
- [4] S. Petry, *Annu. Rev. Biochem.* **2016**, *85*, 659–683.
- [5] R. Heald, R. Tournebize, T. Blank, R. Sandaltzopoulos, P. Becker, A. Hyman, E. Karsenti, *Nature* **1996**, *382*, 420–425.
- [6] T. C. T. Michaels, A. Šarić, J. Habchi, S. Chia, G. Meisl, M. Vendruscolo, C. M. Dobson, T. P. J. Knowles, *Annu. Rev. Phys. Chem.* **2018**, *69*, 273–298.
- [7] G. Ozorowski, J. Pallesen, N. De Val, D. Lyumkis, C. A. Cottrell, J. L. Torres, J. Copps, R. L. Stanfield, A. Cupo, P. Pugach, et al., *Nature* **2017**, *547*, 360–361.
- [8] G. Doitsh, W. C. Greene, *Cell Host Microbe* **2016**, *19*, 280–291.
- [9] R. A. Stanton, K. M. Gernert, J. H. Nettles, R. Aneja, *Med. Res. Rev.* **2011**, *31*, 443–481.
- [10] A. E. Modell, S. L. Blosser, P. S. Arora, *Trends Pharmacol. Sci.* **2016**, *37*, 702–713.
- [11] S. A. Andrei, E. Sijbesma, M. Hann, J. Davis, G. O'Mahony, M. W. D. Perry, A. Karawajczyk, J. Eickhoff, L. Brunsveld, R. G. Doveston, et al., *Expert Opin. Drug Discovery* **2017**, *12*, 925–940.
- [12] P. Schuck, *Biophys. Rev.* **2013**, *5*, 159–171.
- [13] A. D. Hanlon, M. I. Larkin, R. M. Reddick, *Biophys. J.* **2010**, *98*, 297–304.

- [14] A. C. Leney, A. J. R. Heck, *J. Am. Soc. Mass Spectrom.* **2017**, *28*, 5–13.
- [15] W. Ma, L. Yang, L. He, *J. Pharm. Anal.* **2018**, *8*, 147–152.
- [16] H. H. Nguyen, J. Park, S. Kang, M. Kim, *Sensors* **2015**, *15*, 10481–10510.
- [17] Y. Liang, *Acta Biochim. Biophys. Sin.* **2008**, *40*, 565–576.
- [18] J. Enderlein, I. Gregor, D. Patra, T. Dertinger, U. B. Kaupp, *ChemPhysChem* **2005**, *6*, 2324–2336.
- [19] M. P. Goldschen-Ohm, D. S. White, V. A. Klenchin, B. Chanda, R. H. Goldsmith, *Angew. Chem. Int. Ed.* **2017**, *56*, 2399–2402; *Angew. Chem.* **2017**, *129*, 2439–2442.
- [20] V. Aggarwal, T. Ha, *Curr. Opin. Struct. Biol.* **2016**, *41*, 225–232.
- [21] P. Schuck, H. Zhao, *Methods Mol. Biol.* **2010**, *627*, 15–54.
- [22] J. Liu, J. D. Andya, S. J. Shire, *AAPS J.* **2006**, *8*, E580–E589.
- [23] L. L. Sorret, M. A. DeWinter, D. K. Schwartz, T. W. Randolph, *Biophys. J.* **2016**, *111*, 1831–1842.
- [24] K. J. Vincent, M. Zurini, *Biotechnol. J.* **2012**, *7*, 1444–1450.
- [25] D. Cole, G. Young, A. Weigel, A. Sebesta, P. Kukura, *ACS Photonics* **2017**, *4*, 211–216.
- [26] G. Young, N. Hundt, D. Cole, A. Fineberg, J. Andrecka, A. Tyler, A. Olerinyova, A. Ansari, E. G. Marklund, M. P. Collier, et al., *Science* **2018**, *360*, 423–427.
- [27] K. Häußermann, G. Young, P. Kukura, H. Dietz, *Angew. Chem. Int. Ed.* **2019**, *58*, 7662–7667; *Angew. Chem.* **2019**, *131*, 7744–7749.
- [28] D. Wu, G. Piszczek, *Anal. Biochem.* **2020**, 592:113575.
- [29] J. M. Hayes, E. F. J. Cosgrave, W. B. Struwe, M. Wormald, G. P. Davey, R. Jefferis, P. M. Rudd, *Curr. Top. Microbiol. Immunol.* **2014**, 165–199.
- [30] A. Praetor, R. M. Jones, W. L. Wong, W. Hunziker, *J. Mol. Biol.* **2002**, *321*, 277–284.
- [31] Y. N. Abdiche, Y. A. Yeung, J. Chaparro-Riggers, I. Barman, P. Strop, S. M. Chin, A. Pham, G. Bolton, D. McDonough, K. Lindquist, et al., *MAbs* **2015**, *7*, 331–343.
- [32] N. Zijlstra, F. Dingfelder, B. Wunderlich, F. Zosel, S. Benke, D. Nettels, B. Schuler, *Angew. Chem. Int. Ed.* **2017**, *56*, 7126–7129; *Angew. Chem.* **2017**, *129*, 7232–7235.
- [33] Y. Li, W. Struwe, P. Kukura, *bioRxiv* **2020**, <https://doi.org/10.1101/2020.01.14.904755>.
- [34] P. Sonn-Segev, A. Belacic, K. Bodrug, T. Young, G. VanderLinden, R. Schulman, B. Schimpf, J. Friedrich, T. Dip, P. V. Schwartz, T. Bauer, B. Peters, J. M. Struwe, W. Benesch, J. Brown, N. Haselbach, D. Kukura, *bioRxiv* **2019**, <https://doi.org/10.1101/864553>.

Manuscript received: January 30, 2020

Revised manuscript received: March 11, 2020

Accepted manuscript online: March 13, 2020

Version of record online: April 2, 2020